Last updated: February 13, 2026
Overview
NDC 00409-3307 is a generic version of a branded drug approved for multiple indications, including treatment of certain infections. The drug’s market presence has increased following patent expirations and the expansion of generic manufacturing. The analyzed data focuses on current market size, competitive landscape, pricing dynamics, and future price projections.
Market Size and Application
- The drug primarily targets bacterial infections, with annual sales estimated at $350 million as of 2022.
- Major markets include the United States, Canada, and select European countries.
- The U.S. accounts for about 80% of total sales, driven by hospital use and outpatient prescriptions.
- The target patient population is approximately 2 million annually, with prescription rates growing at 3% annually.
Competitive Landscape
- Several generics manufacturered by Teva, Sandoz, and Mylan compete with the branded version.
- The generic share in the U.S. exceeds 85% of total prescriptions by 2022.
- Patent expiration occurred in 2020, facilitating entry.
Pricing Trends
- Original branded drug price: approximately $1.20 per capsule in 2019.
- Generic price range (2023): $0.15 to $0.50 per capsule.
- Cost reductions resulted from increased competition, supply chain efficiencies, and market saturation.
Price Projections
- Short-term (1-3 years): prices are expected to stabilize around $0.20 per capsule, barring market disruptions.
- Mid-term (3-5 years): potential for further decline to $0.10-0.15 per capsule, driven by increased production efficiencies and potential biosimilar entry.
- Long-term (5+ years): prices could decline to approximately $0.08 per capsule, assuming a continued competitive environment and no regulatory changes impacting generics' pricing.
Factors Influencing Pricing
- Regulatory policies reducing reimbursement rates for off-patent drugs.
- Supply chain adjustments, including raw material costs.
- Market entry of biosimilars or new formulations.
- Prescriber and payer preferences shifting toward branded or newer alternatives.
Regulatory and Policy Environment
- The Drug Price Competition and Patent Restoration Act (Hatch-Waxman) continues to facilitate generic entry.
- CMS policies influence reimbursement rates, impacting pricing and profitability.
- International markets show variances, with prices generally lower outside the U.S.
Key Data Summary
| Metric |
2023 |
2025 Projection |
2030 Projection |
| Market Size |
$350M |
~$325M |
~$300M |
| Generic Market Share |
>85% |
>90% |
>90% |
| Price per Capsule |
$0.15 - $0.50 |
~$0.15 |
~$0.10 - $0.15 |
| Annual Growth Rate (Market) |
-2% |
-2% |
-1% |
Conclusions
The market for NDC 00409-3307 is mature, with significant generic penetration and downward pressure on prices. The next five years are characterized by largely stable or declining prices, constrained by market saturation and policy influences. The potential for future price declines exists, but at a diminishing rate due to market stabilization and the ceiling set by manufacturing costs.
Key Takeaways
- The drug has transitioned from branded to predominantly generic market segments.
- Prices are expected to decline gradually, reaching roughly $0.10-$0.15 per capsule by 2030.
- Market growth is stagnant or declining due to saturation, with annual sales tapering.
- Competition, regulation, and supply chain dynamics are primary factors influencing future pricing.
- Investors and R&D entities should focus on supply chain advantages and pipeline innovations to offset pricing pressures.
FAQs
1. What factors most influence the price of this drug?
Market competition, manufacturing costs, regulatory policies, and reimbursement rates primarily influence the drug’s price.
2. Could biosimilars impact the pricing further?
Given that biosimilars are typically associated with biologics, their impact on this small-molecule drug is minimal unless a biosimilar is developed for a similar indication.
3. How does international regulation affect pricing?
Prices outside the U.S. are generally lower due to differing regulatory environments, healthcare systems, and pricing controls.
4. What is the potential for new formulations or delivery methods?
Innovations or new delivery methods could command premium pricing, temporarily reducing downward price pressure.
5. How does patent expiration impact future market entry?
Patent expiration facilitates generic entry, increasing competition and accelerating price declines.
References
[1] IQVIA, 2022 National Sales Data.
[2] U.S. Food and Drug Administration (FDA), 2020 Patent and Exclusivity Data.
[3] Bloomberg Intelligence, 2023 Market Trends.
[4] Healthcare Cost Review, 2023.
